| 000 | 05357nam a22005775i 4500 | ||
|---|---|---|---|
| 001 | 978-1-0716-3311-3 | ||
| 003 | DE-He213 | ||
| 005 | 20260610083647.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 230630s2023 xxu| s |||| 0|eng d | ||
| 020 |
_a9781071633113 _9978-1-0716-3311-3 |
||
| 024 | 7 |
_a10.1007/978-1-0716-3311-3 _2doi |
|
| 050 | 4 | _aRC321-580 | |
| 072 | 7 |
_aPSAN _2bicssc |
|
| 072 | 7 |
_aSCI089000 _2bisacsh |
|
| 072 | 7 |
_aPSAN _2thema |
|
| 082 | 0 | 4 |
_a612.8 _223 |
| 245 | 1 | 0 |
_aComputational Modeling of Drugs Against Alzheimer’s Disease _h[electronic resource] / _cedited by Kunal Roy. |
| 250 | _a2nd ed. 2023. | ||
| 264 | 1 |
_aNew York, NY : _bSpringer US : _bImprint: Humana, _c2023. |
|
| 300 |
_aXVII, 493 p. 176 illus., 122 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 341 | 0 |
_bTable of contents navigation _2onix |
|
| 341 | 0 |
_bSingle logical reading order _2onix |
|
| 341 | 0 |
_bShort alternative textual descriptions _2onix |
|
| 341 | 0 |
_bUse of color is not sole means of conveying information _2onix |
|
| 341 | 0 |
_bUse of high contrast between text and background color _2onix |
|
| 341 | 0 |
_bNext / Previous structural navigation _2onix |
|
| 341 | 0 |
_bAll non-decorative content supports reading without sight _2onix |
|
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aNeuromethods, _x1940-6045 ; _v203 |
|
| 505 | 0 | _aRecent Progress in the Treatment Strategies of Alzheimer’s Disease -- Understanding the Mechanisms of Amyloid Beta (Aβ) Aggregation by Computational Modeling -- Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents -- Modeling of BACE-1 Inhibitors as Anti-Alzheimer’s Agents -- Computational Modeling of Kinase Inhibitors as Anti-Alzheimer Agents -- Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzheimer’s Disease -- Computational Modeling Approaches in Search of Anti-Alzheimer Agents: Case Studies of Phosphodiesterase Inhibitors -- Recent Advances in Computational Modeling of Multi-Targeting Inhibitors as Anti-Alzheimer Agents -- Computational Modeling of PET and SPECT Imaging Agents as Diagnostics for Alzheimer’s Disease -- Computational Modeling of DYRK1A Inhibitors as Potential Anti-Alzheimer Agents -- Computational Modeling of MAO Inhibitors as Anti-Alzheimer Agents -- Computational Modeling of Phosphodiesterase Inhibitors as Anti-Alzheimer Agents -- Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer’s Disease -- Basic Information Science Methods for Insight into Neurodegenerative Pathogenesis -- Network Pharmacology for Drug Repositioning in Anti-Alzheimer's Drug Development -- Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs. | |
| 520 | _aThis second edition volume expands on the previous edition with updated descriptions on different computational methods encompassing ligand-based, structure-based, and combined approaches with their recent applications in anti-Alzheimer drug design. Different background topics like recent advancements in research on the development of novel therapies and their implications in the treatment of Alzheimer’s Disease (AD) have also been covered for completeness. Special topics like basic information science methods for insight into neurodegenerative pathogenesis, drug repositioning and network pharmacology, and online tools to predict ADMET behavior with reference to anti-Alzheimer drug development have also been included. In the Neuromethods series style, chapter include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Computational Modeling of Drugs Against Alzheimer’s Disease, Second Edition is a valuable resource for all researchers and scientists interested in learning more about this important and developing field. | ||
| 532 | 8 | _aAccessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | _aNo reading system accessibility options actively disabled | |
| 532 | 8 | _aPublisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 650 | 0 | _aNeurosciences. | |
| 650 | 1 | 4 | _aNeuroscience. |
| 700 | 1 |
_aRoy, Kunal. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer Nature eBook | |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071633106 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071633120 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071633137 |
| 830 | 0 |
_aNeuromethods, _x1940-6045 ; _v203 |
|
| 856 | 4 | 0 | _uhttps://doi.org/10.1007/978-1-0716-3311-3 |
| 912 | _aZDB-2-PRO | ||
| 999 |
_c6459 _d6459 |
||